(Q37895525)

24 August 2017

1 reference

title

Improvement of cardiac parameters in patients with acromegaly treated with medical therapies (English)

1 reference

24 August 2017

1

Annamaria Colao

1 reference

24 August 2017

publication date

1 March 2012

1 reference

24 August 2017

1 reference

24 August 2017

volume

15

1 reference

24 August 2017

issue

1

1 reference

24 August 2017

page(s)

50-58

1 reference

https://scigraph.springernature.com/pub.10.1007/s11102-011-0318-z

24 August 2017

exact match

0 references

cites work

Medical progress: Acromegaly

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Epidemiology of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Systemic complications of acromegaly: epidemiology, pathogenesis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Growth hormone and the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Cardiac manifestations of GH deficiency after treatment for acromegaly: a comparison to patients with biochemical remission and controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Late potentials and ventricular arrhythmias in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Hypertension in acromegaly and in the normal population: prevalence and determinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Improvement of endothelial dysfunction in acromegaly after transsphenoidal surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Effect of transsphenoidal surgery on sleep apnoea in acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Successful reversal of sleep apnoea syndrome following treatment for acromegaly, confirmed by polygraphic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Sleep-disordered breathing in acromegalics--relation of hormonal levels and quantitative sleep study by means of bedside oximeter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Nocturnal breathing abnormalities in acromegaly after adenomectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Guidelines for acromegaly management: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Somatostatin receptor subtype expression in the human heart: differential expression by myocytes and fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Short term reduction of left ventricular mass in primary hypertrophic cardiomyopathy by octreotide injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Effect of Sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

ACROSTUDY: Status Update on 469 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Euglycemic hyperinsulinemia differentially modulates circulating total and acylated-ghrelin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

The GH-IGF-I axis and the cardiovascular system: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Improvement of intrinsic myocardial contractility and cardiac fibrosis degree in acromegalic patients treated with somatostatin analogues: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Evaluation of cardiac structure by echoreflectivity analysis in acromegaly: effects of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Acromegalic cardiopathy improves after treatment with increasing doses of octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Treatment of acromegaly improves myocardial abnormalities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Treatment with Growth Hormone Receptor Antagonist in Acromegaly: Effect on Cardiac Structure and Performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-011-0318-Z

Investigation of early atherosclerotic changes in acromegalic patients

21 January 2018

1 reference

12 December 2020

Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion

1 reference

12 December 2020

Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly

1 reference

12 December 2020

Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients

1 reference

12 December 2020

The cardiovascular effects of octreotide treatment in acromegaly: an echocardiographic study

1 reference

12 December 2020

Octreotide treatment increases exercise capacity in patients with acromegaly

1 reference

12 December 2020

Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria

1 reference

12 December 2020

Exogenously administered growth hormone and insulin-like growth factor-I alter intracellular Ca2+ handling and enhance cardiac performance. In vitro evaluation in the isolated isovolumic buffer-perfused rat heart

1 reference

12 December 2020

Effect of octreotide pretreatment on surgical outcome in acromegaly

1 reference

12 December 2020

Myocardial systolic strain abnormalities in patients with acromegaly: a prospective color Doppler imaging study

1 reference

12 December 2020

Acromegalic heart disease: influence of treatment of the acromegaly on the heart.

1 reference

12 December 2020

Factors influencing mortality in acromegaly

1 reference

12 December 2020

Cardiovascular consequences of early-onset growth hormone excess

1 reference

12 December 2020

Insulin-like growth factor I retards apoptotic signaling induced by ethanol in cardiomyocytes

1 reference

12 December 2020

Increased prevalence of regurgitant valvular heart disease in acromegaly

1 reference

12 December 2020

Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies

1 reference

12 December 2020

Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients

1 reference

12 December 2020

Cardiovascular aspects in acromegaly: effects of treatment

1 reference

12 December 2020

Cardiac morphology in rats with growth hormone-producing tumours

1 reference

12 December 2020

Characterization of premature atherosclerosis of carotid arteries in acromegalic patients

1 reference

12 December 2020

Effects of octreotide on left ventricular mass in acromegaly

1 reference

12 December 2020

Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients

1 reference

12 December 2020

Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly

1 reference

12 December 2020

High prevalence of cardiac hypertophy without detectable signs of fibrosis in patients with untreated active acromegaly: an in vivo study using magnetic resonance imaging

1 reference

12 December 2020

Progression of cardiovascular disease in acromegalic patients treated by external pituitary irradiation.

1 reference

12 December 2020

Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes

1 reference

12 December 2020

10.1007/S11102-011-0318-Z

Identifiers

DOI

1 reference

24 August 2017

1 reference